The Russian government is considering legalizing the parallel importation of drugs into the country in an attempt to force foreign producers to reduce the prices for their range in Russia.
Legalization of parallel imports of drugs has been under discussion in Russia for the last several years. The local Federal Antimonopoly Service has been lobbying for this measure for more than three years, despite the fact that the majority of foreign drugmakers have opposed these plans.
The same position is shared by the Association of European Businesses, according to which this will create additional threats to the health of Russian consumers and will result in the influx of low-quality drugs to the local market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze